Table 2.
Human Papillomavirus Prevalence Among Females Aged 14–34 Years, According to Age Group—National Health and Nutrition Examination Survey, 2003–2014
| Prevaccine Era (2003–2006) | Vaccine Era (2007–2010) | Vaccine Era (2011–2014) | Comparison of 2011–2014 to 2003–2006 | ||
|---|---|---|---|---|---|
|
|
|||||
| Age Group and HPV Typesa % | (95% CI) | (95% CI) | (95% CI) | PR (95% CI) | aPR (95% CI)b |
| 14–19 y | |||||
| Any HPV | 32.9 (29.5–36.5) | 26.1 (22.3–30.3) | 25.9 (21.7–30.6) | 0.79 (.65–.96) | 0.84 (.71–.99) |
| Non-4vHPV | 31.2 (27.9–34.8) | 25.3 (21.4–29.5) | 25.5 (21.3–30.2) | 0.82 (.67–1.00) | 0.88 (.74–1.04) |
| Non-4vHPV HR | 20.7 (17.8–24.0) | 16.4 (12.9–20.7) | 15.4 (11.5–20.2) | 0.74 (.54–1.01) | 0.83 (.64–1.09) |
| HPV types 31, 33, 45 | 4.3 (3.1–6.1) | 1.7 (.9–3.2) | 2.4 (1.1–5.4)c | 0.56 (.24–1.33) | 0.71 (.29–1.77) |
| 4vHPV | 11.5 (9.1–14.4) | 5.0 (3.8–6.6) | 3.3 (1.9–5.8) | 0.29 (.16–.52) | 0.29 (.16–.53) |
|
| |||||
| 20–24 y | |||||
| Any HPV | 53.7 (45.9–61.4) | 59.7 (53.9–65.4) | 56.7 (50.9–62.3) | 1.05 (.89–1.26) | 1.00 (.86–1.16) |
| Non-4vHPV | 50.7 (43.3–58.0) | 57.4 (51.3–63.3) | 55.8 (49.9–61.6) | 1.10 (.92–1.31) | 1.05 (.90–1.23) |
| Non-4vHPV HR | 32.9 (26.7–39.7) | 37.4 (32.4–42.7) | 34.5 (27.7–42.0) | 1.05 (.79–1.39) | 1.04 (.78–1.39) |
| HPV types 31, 33, 45 | 7.8 (5.0–12.1) | 6.4 (4.3–9.4) | 4.7 (2.6–8.3) | 0.60 (.29–1.24) | 0.60 (.26–1.38) |
| 4vHPV | 18.5 (14.9–22.8) | 19.9 (15.4–25.3) | 7.2 (4.7–11.1) | 0.39 (.24–.63) | 0.35 (.21–.58) |
|
| |||||
| 25–29 y | |||||
| Any HPV | 46.8 (42.9–50.8) | 50.8 (45.9–55.6) | 44.7 (38.9–50.6) | 0.96 (.82–1.11) | 0.96 (.82–1.13) |
| Non-4vHPV | 43.8 (38.9–48.9) | 48.6 (43.7–53.6) | 43.7 (37.7–49.9) | 1.00 (.84–1.19) | 1.02 (.85–1.22) |
| Non-4vHPV HR | 24.6 (19.0–31.2) | 28.4 (23.2–34.3) | 25.5 (21.3–30.3) | 1.04 (.77–1.40) | 0.98 (.71–1.34) |
| HPV types 31, 33, 45 | 5.8 (3.6–9.0) | 6.3 (4.0–9.8) | 6.0 (3.7–9.7) | 1.04 (.54–2.00) | 1.24 (.60–2.56) |
| 4vHPV | 11.8 (8.8–15.6) | 13.1 (10.0–17.2) | 8.8 (6.3–12.1) | 0.75 (.49–1.14) | 0.76 (.51–1.15) |
|
| |||||
| 30–34 y | |||||
| Any HPV | 47.9 (42.3–53.5) | 40.1 (33.8–46.7) | 41.3 (35.8–47.0) | 0.86 (.72–1.03) | 0.78 (.66–.93) |
| Non-4vHPV | 44.5 (39.1–50.1) | 37.8 (31.6–44.5) | 39.2 (33.6–45.0) | 0.88 (.73–1.06) | 0.80 (.67–.97) |
| Non-4vHPV HR | 21.0 (15.5–27.8) | 20.1 (15.6–25.6) | 18.3 (15.1–21.9) | 0.87 (.62–1.22) | 0.80 (.54–1.18) |
| HPV types 31, 33, 45 | 4.1 (2.2–7.6)c | 4.0 (2.5–6.4) | 4.1 (2.4–6.8) | 1.00 (.45–2.21) | 0.74 (.33–1.66) |
| 4vHPV | 9.5 (6.7–13.2) | 8.9 (6.5–11.9) | 7.1 (5.1–9.9) | 0.75 (.47–1.19) | 0.71 (.44–1.15) |
All prevalence estimates and 95% CIs are weighted.
Abbreviations: 4vHPV, quadrivalent human papillomavirus; aPR, adjusted prevalence ratio; CI, confidence interval; HPV, human papillomavirus; HR, high risk; PR, prevalence ratio.
Any HPV: HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 63, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39. Non-4vHPV: HPV types 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 63, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39. Non-4vHPV HR: HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. 4vHPV: HPV types 6, 11, 16, 18.
Adjusted for race/ethnicity, poverty index, and number of lifetime partners.
Relative standard error >30%.